Switzerland· 70199001
Stoboclo 60 mg, solution injectable en seringue préremplie
A denosumab product containing denosumabum, registered in Switzerland by IQONE HEALTHCARE SWITZERLAND SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Denosumab is registered in 16 of 19 countries.
Countries holding a registration under ATC M05BX04 (denosumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Denosumab · ATC M05BX04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of denosumab costs, country by country.
Normalised to the WHO defined daily dose (0.33 mg), so markets compare like for like.
- Switzerland: $1.37 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Denosumab · price per daily dose (0.33 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.37
The record
At a glance
Swissmedic (Switzerland)- Active substance
- denosumabum
- Manufacturer
- IQONE HEALTHCARE SWITZERLAND SA
- Country
- Switzerland (CH)
- ATC code
- M05BX04
- ATC class
- Denosumab
- Defined daily dose
- 0.33 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680701990010Fertigspr 1 StkCHF 206.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
262 interactions on record for denosumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Denosumab · interactions on record
262 records
- 3 severe
- 259 moderate
Most severe, free to view
- EtelcalcetideH05BX04severe
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Denosumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandIzambyMabxience Research SL
- BelgiumEvfraxy 60 mg/mlBiosimilar Collaborations Ireland
- IcelandProliaAmgen Europe B.V.*
- CzechiaACVYBRAReddy Holding GmbH, Augsburg
- FinlandAcvybraReddy Holding GmbH
- SwedenAcvybra 60 mg Injektionsvätska, lösning i förfylld sprutaReddy Holding GmbH
- NetherlandsAcvybra 60 mg oplossing voor injectie in een voorgevulde spuitReddy Holding GmbH
- IrelandAcvybra 60 mg solution for injection in pre-filled syringeReddy Holding GmbH
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Enwylma, Ponlimsi
- Iceland · Bildyos, Bilprevda
- Liechtenstein · Bildyos, Bilprevda
- Norway · Bildyos, Bilprevda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c5dd6839-c550-427a-8646-9c1f708b5884 GET /v1/drugs/c5dd6839-c550-427a-8646-9c1f708b5884?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "denosumabum 60 mg",
"valid_from": "2026-03-01",
"limitations": "[{\"description\":\"Behandlung der Osteoporose bei postmenopausalen Frauen (Reduktion um mehr als 2,5 Standard-Abweichungen bei der Osteodensitometrie oder bei Fraktur). Begleitbehandlung bei Frauen mit Mammakarzinom unter adjuvanter Behandlung mit Aromatasehemmern und bei Männern mit Prostatakarzinom unter Hormonablation, wenn ein erhöhtes Frakturrisiko vorliegt. Nach Abschluss der adjuvanten Behandlung mit Aromatasehemmern oder der Hormonablation ist auch die Behandlung mit Stoboclo zu beenden.<br>\\nBehandlung zur Erhöhung der Knochenmineraldichte bei Männern mit Osteoporose und erhöhtem Frakturrisiko.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-03-01\"}]",
"galenic_form": "Inj Lös 60 mg/ml",
"therapeutic_area": null,
"sl_inclusion_date": "2026-03-01",
"self_retention_pct": 10
}See everything about denosumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.